Article

Allergan enters definitive merger agreement with Inamed

Allergan Inc. and Inamed Corp. entered a definitive agreement and plan of merger. For each outstanding common share of Inamed, Allergan will exchange either $84 in cash or 0.8498 of a share of Allergan common stock. The exchange began on Nov. 21, 2005, and will expire Jan. 9, 2006 (subject to extension or early termination).

"The signing of the merger agreement by both parties marks a significant milestone in the process of combining the two companies and delivering on our vision to create a leading world franchise in the high-growth medical aesthetics arena," said David E.I. Pyott, Allergan's chairman of the board, president, and chief executive officer.

Inamed also entered into a termination agreement with Ipsen Ltd., so that Ipsen will retain its rights to botulinum toxin type A (Reloxin). Through the agreement, both companies release each other of distribution obligations for the product.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
© 2025 MJH Life Sciences

All rights reserved.